Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY M FULLER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1356347306
CMS profile
151762
Location
KELLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$4,839.68

151 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,219.68 148
Consulting Fee $1,600.00 2
Gift $20.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY M FULLER

NPI 1356347306 · CMS profile ID 151762

Allopathic & Osteopathic Physicians / Family Medicine

KELLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356347306?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY M FULLER, NPI 1356347306, CMS profile ID 151762. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356347306?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GREGORY M FULLER, NPI 1356347306, CMS profile ID 151762. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356347306?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GREGORY M FULLER, NPI 1356347306, CMS profile ID 151762, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1356347306?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

151 matching records · $4,839.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 151 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 151.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $1.3808/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802298193 CMS
GlaxoSmithKline, LLC. $18.1808/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802481891 CMS
Amgen Inc. $123.8308/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826343513 CMS
Amgen Inc. $17.9208/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826343493 CMS
AbbVie Inc. $2.6808/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794525297 CMS
GlaxoSmithKline, LLC. $16.4008/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802472259 CMS
AbbVie Inc. $18.5908/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794525293 CMS
Novo Nordisk Inc $12.4008/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811694871 CMS
AbbVie Inc. $4.5407/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794525290 CMS
AstraZeneca Pharmaceuticals LP $12.6507/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830066693 CMS
Chugai Pharmaceutical Co., Ltd. $400.0007/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835916127 CMS
Biohaven Pharmaceuticals, Inc. $1,200.0007/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852494327 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.6207/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819930115 CMS
GlaxoSmithKline, LLC. $114.4207/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802223623 CMS
PFIZER INC. $15.1607/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833505821 CMS
Biohaven Pharmaceuticals, Inc. $16.0107/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852494325 CMS
Amarin Pharma Inc. $14.6007/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815335781 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $28.9307/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763721612 CMS
Novo Nordisk Inc $16.7607/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810644013 CMS
Amgen Inc. $13.4607/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826343489 CMS
Eisai Inc. $12.1207/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833777091 CMS
AbbVie Inc. $103.0507/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794525287 CMS
Biohaven Pharmaceuticals, Inc. $21.1307/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852494323 CMS
AstraZeneca Pharmaceuticals LP $12.9807/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829565219 CMS
Antares Pharma, Inc. $22.2806/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827494425 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.3306/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763721614 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.6606/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819930113 CMS
AstraZeneca Pharmaceuticals LP $124.9906/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829491481 CMS
Biohaven Pharmaceuticals, Inc. $119.3906/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852494321 CMS
Novo Nordisk Inc $12.1506/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811450173 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.1006/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763721616 CMS
AbbVie Inc. $124.4006/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794525283 CMS
AbbVie Inc. $103.8506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794525279 CMS
Lilly USA, LLC $11.3406/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819176035 CMS
AstraZeneca Pharmaceuticals LP $18.0306/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829617099 CMS
Amgen Inc. $13.6606/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826343485 CMS
Optos, Inc. $13.6806/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853263743 CMS
PFIZER INC. $20.0006/03/2021 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833592819 CMS
SANOFI-AVENTIS U.S. LLC $11.3506/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843458247 CMS
Amgen Inc. $112.7306/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825339475 CMS
AbbVie Inc. $15.4505/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794525275 CMS
Paratek Pharmaceuticals, Inc. $13.4305/27/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 813503071 CMS
Amarin Pharma Inc. $17.1705/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815276179 CMS
Novo Nordisk Inc $15.7505/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810776825 CMS
GlaxoSmithKline, LLC. $13.1505/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803131619 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.3105/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819930111 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.0005/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763721618 CMS
Janssen Pharmaceuticals, Inc $11.1305/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788146065 CMS
PFIZER INC. $13.6505/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833528683 CMS
Amgen Inc. $25.4205/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825339471 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,451.67 126
PY2020 $2,364.00 121
PY2021 $4,839.68 151
PY2022 $2,494.72 104
PY2023 $2,406.45 116
PY2024 $2,756.58 100
PY2025 $3,468.03 72

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $549,453.17 189
PY2024 Principal investigator $1,603,746.74 109
PY2023 Principal investigator $1,867,749.97 231
PY2022 Recipient $913.00 1
PY2022 Principal investigator $2,515,632.10 204
PY2021 Principal investigator $2,036,466.68 95
PY2020 Principal investigator $2,474,600.46 96
PY2019 Principal investigator $499,406.87 98

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

189 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $3,818.50 12/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964664
Principal investigator 1 ModernaTX, Inc. $1,348.56 11/20/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964668
Principal investigator 1 ModernaTX, Inc. $1,411.44 11/20/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964670
Principal investigator 1 ModernaTX, Inc. $255.96 11/20/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964744
Principal investigator 1 ModernaTX, Inc. $223.56 11/20/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964814
Principal investigator 1 ModernaTX, Inc. $39.39 11/20/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964818
Principal investigator 1 ModernaTX, Inc. $250.00 11/19/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964734
Principal investigator 1 ModernaTX, Inc. $250.00 11/19/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964804
Principal investigator 1 ModernaTX, Inc. $250.00 11/19/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964870
Principal investigator 1 ModernaTX, Inc. $1,800.00 11/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005017
Principal investigator 1 ModernaTX, Inc. $725.00 11/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005049
Principal investigator 1 ModernaTX, Inc. $1,400.00 11/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005065
Principal investigator 1 ModernaTX, Inc. $250.00 10/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964658
Principal investigator 1 ModernaTX, Inc. $26.00 10/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964660
Principal investigator 1 ModernaTX, Inc. $969.03 10/24/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964740
Principal investigator 1 ModernaTX, Inc. $2,000.00 10/16/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964666
Principal investigator 1 ModernaTX, Inc. $1,800.00 10/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964816
Principal investigator 1 ModernaTX, Inc. $1,174.50 10/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964738
Principal investigator 1 Genentech, Inc. $203.00 09/24/2025 Non-covered Recipient Entity
SCR Of Texas, LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211653462
Principal investigator 1 ModernaTX, Inc. $1,999.61 09/24/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964810
Principal investigator 1 ModernaTX, Inc. $998.00 09/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005023
Principal investigator 1 ModernaTX, Inc. $775.00 09/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005061
Principal investigator 1 ModernaTX, Inc. $250.00 09/19/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964736
Principal investigator 1 ModernaTX, Inc. $250.00 09/19/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964874
Principal investigator 1 ModernaTX, Inc. $250.00 08/28/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964586
Principal investigator 1 ModernaTX, Inc. $77.04 08/28/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005079
Principal investigator 1 ModernaTX, Inc. $4,060.76 08/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964730
Principal investigator 1 Genentech, Inc. $1,200.00 08/20/2025 Non-covered Recipient Entity
SCR Of Texas, LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211653467
Principal investigator 1 ModernaTX, Inc. $540.00 08/20/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964724
Principal investigator 1 ModernaTX, Inc. $864.00 08/20/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964846
Principal investigator 1 Genentech, Inc. $2,176.00 08/13/2025 Non-covered Recipient Entity
SCR Of Texas, LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211653439
Principal investigator 1 ModernaTX, Inc. $11,740.25 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964592
Principal investigator 1 ModernaTX, Inc. $53,116.12 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964596
Principal investigator 1 ModernaTX, Inc. $8,761.50 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964600
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964602
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964604
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964606
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964632
Principal investigator 1 ModernaTX, Inc. $75.00 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964636
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964644
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964652
Principal investigator 1 ModernaTX, Inc. $8,604.56 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964682
Principal investigator 1 ModernaTX, Inc. $51,095.25 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964684
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964694
Principal investigator 1 ModernaTX, Inc. $1,350.00 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964696
Principal investigator 1 ModernaTX, Inc. $75.00 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964698
Principal investigator 1 ModernaTX, Inc. $75.00 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964700
Principal investigator 1 ModernaTX, Inc. $75.00 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964702
Principal investigator 1 ModernaTX, Inc. $1,640.25 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964706
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964716
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964718
Principal investigator 1 ModernaTX, Inc. $108.00 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964722
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964754
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964756
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964758
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964762
Principal investigator 1 ModernaTX, Inc. $3,004.00 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964772
Principal investigator 1 ModernaTX, Inc. $53.00 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964774
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964778
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964780
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964782
Principal investigator 1 ModernaTX, Inc. $75.00 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964784
Principal investigator 1 ModernaTX, Inc. $172.80 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964792
Principal investigator 1 ModernaTX, Inc. $2,288.93 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964794
Principal investigator 1 ModernaTX, Inc. $75.00 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964796
Principal investigator 1 ModernaTX, Inc. $75.00 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964836
Principal investigator 1 ModernaTX, Inc. $13,344.75 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964838
Principal investigator 1 ModernaTX, Inc. $75.00 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964842
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964616
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964622
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964624
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964626
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964630
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964634
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964654
Principal investigator 1 ModernaTX, Inc. $500.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964678
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964680
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964692
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964708
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964712
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964752
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964764
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964766
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964798
Principal investigator 1 ModernaTX, Inc. $500.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964832
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964848
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964854
Principal investigator 1 ModernaTX, Inc. $75.00 08/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964856
Principal investigator 1 ModernaTX, Inc. $250.00 08/06/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964746
Principal investigator 1 ModernaTX, Inc. $1,272.83 08/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964732
Principal investigator 1 ModernaTX, Inc. $300.00 08/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964742
Principal investigator 1 Genentech, Inc. $2,308.00 07/25/2025 Non-covered Recipient Entity
SCR Of Texas, LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211653441
Principal investigator 1 ModernaTX, Inc. $726.77 07/23/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964802
Principal investigator 1 Genentech, Inc. $280.00 07/16/2025 Non-covered Recipient Entity
SCR Of Texas, LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211653474
Principal investigator 1 ModernaTX, Inc. $2,726.38 06/25/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964868
Principal investigator 1 ModernaTX, Inc. $8,189.38 06/18/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005025
Principal investigator 1 ModernaTX, Inc. $250.00 06/02/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964812
Principal investigator 1 Genentech, Inc. $1,154.00 05/30/2025 Non-covered Recipient Entity
SCR Of Texas, LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211653385
Principal investigator 1 ModernaTX, Inc. $250.00 05/28/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964674
Principal investigator 1 ModernaTX, Inc. $5,790.84 05/28/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005027
Principal investigator 1 ModernaTX, Inc. $1,490.64 05/28/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005031
Principal investigator 1 ModernaTX, Inc. $24,137.12 05/28/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005037
Principal investigator 1 ModernaTX, Inc. $343.20 05/28/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005053
Principal investigator 1 Genentech, Inc. $1,218.00 05/23/2025 Non-covered Recipient Entity
SCR Of Texas, LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211653366
Principal investigator 1 ModernaTX, Inc. $4,060.76 05/23/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964726
Principal investigator 1 ModernaTX, Inc. $42.90 05/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005041
Principal investigator 1 ModernaTX, Inc. $1,105.00 05/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005043
Principal investigator 1 Genentech, Inc. $203.00 05/21/2025 Non-covered Recipient Entity
SCR Of Texas, LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211653420
Principal investigator 1 ModernaTX, Inc. $343.20 05/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005047
Principal investigator 1 ModernaTX, Inc. $250.00 05/16/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964800
Principal investigator 1 ModernaTX, Inc. $1,850.00 05/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964642
Principal investigator 1 ModernaTX, Inc. $172.80 05/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964788
Principal investigator 1 ModernaTX, Inc. $7,877.25 05/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964830
Principal investigator 1 ModernaTX, Inc. $4,787.53 05/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964872
Principal investigator 1 ModernaTX, Inc. $13,415.76 04/28/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005019
Principal investigator 1 ModernaTX, Inc. $21,551.00 04/28/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005021
Principal investigator 1 ModernaTX, Inc. $7,511.40 04/28/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005075
Principal investigator 1 ModernaTX, Inc. $172.80 04/18/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964608
Principal investigator 1 ModernaTX, Inc. $1,550.00 04/18/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964776
Principal investigator 1 ModernaTX, Inc. $11,028.15 04/18/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964828
Principal investigator 1 ModernaTX, Inc. $172.80 04/16/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964648
Principal investigator 1 ModernaTX, Inc. $23,977.35 04/16/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964704
Principal investigator 1 ModernaTX, Inc. $3,250.00 04/16/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964768
Principal investigator 1 ModernaTX, Inc. $7,408.44 04/09/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005059
Principal investigator 1 ModernaTX, Inc. $172.80 04/04/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964760
Principal investigator 1 ModernaTX, Inc. $3,756.96 04/02/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964728
Principal investigator 1 ModernaTX, Inc. $108.00 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964590
Principal investigator 1 ModernaTX, Inc. $432.00 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964594
Principal investigator 1 ModernaTX, Inc. $1,500.00 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964610
Principal investigator 1 ModernaTX, Inc. $150.00 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964614
Principal investigator 1 ModernaTX, Inc. $6,000.75 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964620
Principal investigator 1 ModernaTX, Inc. $2,250.00 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964646
Principal investigator 1 ModernaTX, Inc. $345.60 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964650
Principal investigator 1 ModernaTX, Inc. $345.60 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964676
Principal investigator 1 ModernaTX, Inc. $108.00 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964686
Principal investigator 1 ModernaTX, Inc. $2,304.45 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964720
Principal investigator 1 ModernaTX, Inc. $1,750.00 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964770
Principal investigator 1 ModernaTX, Inc. $1,500.00 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964790
Principal investigator 1 ModernaTX, Inc. $108.00 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964826
Principal investigator 1 ModernaTX, Inc. $518.40 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964834
Principal investigator 1 ModernaTX, Inc. $1,500.00 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964840
Principal investigator 1 ModernaTX, Inc. $172.80 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964844
Principal investigator 1 ModernaTX, Inc. $500.00 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964850
Principal investigator 1 ModernaTX, Inc. $172.80 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964852
Principal investigator 1 ModernaTX, Inc. $857.25 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964860
Principal investigator 1 ModernaTX, Inc. $2,484.12 04/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964864
Principal investigator 1 Genentech, Inc. $1,154.00 03/26/2025 Non-covered Recipient Entity
HELIOS CR INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211612576
Principal investigator 1 ModernaTX, Inc. $26.00 03/26/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964628
Principal investigator 1 ModernaTX, Inc. $600.00 03/26/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964690
Principal investigator 1 ModernaTX, Inc. $26.00 03/26/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964710
Principal investigator 1 ModernaTX, Inc. $2,000.00 03/26/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964714
Principal investigator 1 ModernaTX, Inc. $5,018.00 03/26/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964750
Principal investigator 1 ModernaTX, Inc. $2,586.12 03/24/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005051
Principal investigator 1 ModernaTX, Inc. $11,925.12 03/24/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005071
Principal investigator 1 ModernaTX, Inc. $6,753.84 03/24/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005077
Principal investigator 1 ModernaTX, Inc. $250.00 03/20/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964672
Principal investigator 1 ModernaTX, Inc. $1,300.00 03/14/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964858
Principal investigator 1 ModernaTX, Inc. $1,050.00 03/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964820
Principal investigator 1 Genentech, Inc. $1,154.00 02/28/2025 Non-covered Recipient Entity
HELIOS CR INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211612554
Principal investigator 1 ModernaTX, Inc. $663.00 02/28/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005039
Principal investigator 1 ModernaTX, Inc. $14,906.40 02/27/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005033
Principal investigator 1 ModernaTX, Inc. $7,498.56 02/27/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005055
Principal investigator 1 ModernaTX, Inc. $19,395.90 02/27/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005063
Principal investigator 1 ModernaTX, Inc. $750.00 02/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964638
Principal investigator 1 ModernaTX, Inc. $28,620.00 02/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964786
Principal investigator 1 ModernaTX, Inc. $2,652.00 02/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005069
Principal investigator 1 ModernaTX, Inc. $300.00 02/14/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964662
Principal investigator 1 Genentech, Inc. $1,154.00 02/07/2025 Non-covered Recipient Entity
HELIOS CR INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211612591
Principal investigator 1 ModernaTX, Inc. $108.00 02/05/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964618
Principal investigator 1 ModernaTX, Inc. $216.00 02/05/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964640
Principal investigator 1 ModernaTX, Inc. $324.00 02/05/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964862
Principal investigator 1 ModernaTX, Inc. $250.00 02/03/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964822
Principal investigator 1 ModernaTX, Inc. $250.00 02/03/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964866
Principal investigator 1 ModernaTX, Inc. $343.20 01/30/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005073
Principal investigator 1 ModernaTX, Inc. $250.00 01/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964588
Principal investigator 1 ModernaTX, Inc. $26.00 01/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964688
Principal investigator 1 ModernaTX, Inc. $5,171.54 01/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964806
Principal investigator 1 ModernaTX, Inc. $8,540.82 01/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964824
Principal investigator 1 ModernaTX, Inc. $7,327.34 01/27/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005029
Principal investigator 1 ModernaTX, Inc. $3,108.48 01/27/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005035
Principal investigator 1 ModernaTX, Inc. $4,635.24 01/27/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005045
Principal investigator 1 ModernaTX, Inc. $7,453.20 01/27/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005067
Principal investigator 1 ModernaTX, Inc. $518.40 01/15/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964598
Principal investigator 1 ModernaTX, Inc. $345.60 01/15/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252964612
Principal investigator 1 ModernaTX, Inc. $208.00 01/15/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964656
Principal investigator 1 ModernaTX, Inc. $2,125.00 01/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005057
Principal investigator 1 ModernaTX, Inc. $250.00 01/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964808
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,535.02 01/06/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185546927
Principal investigator 1 ModernaTX, Inc. $600.00 01/02/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252964748